OGEN (Oragenics) Total Enterprise Value

Oragenics Inc. - graphic logo of issuer OGEN

Oragenics, Inc. (OGEN) develops nasal products to combat infections and neurological conditions, possessing high profit potential following drug certification. This price chart illustrates the enterprise value, which currently stands at -2.15. This price action reflects management restructuring and an updated R&D strategy. Simultaneously, the business is exposed to risks of raw material supply chain disruptions from South Asia due to geopolitical instability.

OGEN (oragenics.com) Total Company Value history from 11/23/2025 to 10/29/2026

Oragenics, Inc. (OGEN) - metric breakdowns and financial figures

- price and consensus price forecast:
Price Rate Chart Oragenics Inc.|OGEN - Analyst Consensus Forecast
- market capitalization data:
Market Value Oragenics|OGEN - Total Company Value
- book capitalization data:
Equity per Share Oragenics|OGEN - Company Book Value|Market Capitalization to Net Assets oragenics.com|OGEN - Company Total Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Oragenics, Inc.|OGEN - Long-Term Debt to Capital|Short-Term Debt to Capital oragenics.com|OGEN - Company Debts|Debt to Net Assets Ratio Oragenics|OGEN - Company Long-Term Debt|Company Current Liabilities Oragenics
Comprehensive company analysis:Oragenics Inc. (OGEN)
Original product of Oragenics, Inc.

Enterprise Value (EV) represents the aggregate buyout price of an asset, combining market capitalization with net debt to determine the actual cost of acquiring a business. For Oragenics, Inc. (OGEN), the current EV level reflects the investment value of upgrading production capacities and preparing facilities for scaling drug output, allowing for an assessment of whether the company's market price is adequate relative to its actual operating assets.

Competitor analysis for Oragenics, Inc.

Full Takeover Company Value Summit Therapeutics plc SMMT|MRNA (Moderna Corp) - Enterprise Value|PCVX: Total Enterprise Value|Total Company Value Tarsus Pharmaceuticals|CRMD (cormedix.com) - Business Value|Total Company Value Seres Therapeutics, Inc. MCRB|Full Business Value Spero Therapeutics Inc|SCYNEXIS, Inc. (SCYX) - Enterprise Value|Value Adjusted for Debt and Cash an2therapeutics.com (ANTX)|Enterprise Value PYPD (PolyPid)|ysbiopharm.com - Enterprise Value|Total Company Value Iterum Therapeutics, plc (ITRM)|PHGE: Value Adjusted for Debt and Cash|SNGX (soligenix.com) - Total Company Value|60 Degrees Pharmaceuticals, Inc. (SXTP) - Real Price to Acquire Entire Company|ONCO (Onconetix, Inc.) - Enterprise Value|Enterprise Value opgen.com (OPGN)